For the quarter ending 2025-09-30, KALV had $68,627K increase in cash & cash equivalents over the period. -$74,056K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-07-31 |
|---|---|---|
| Product revenue, net | 12,266 | - |
| Total operating expenses | 108,001 | - |
| Operating loss | -95,735 | - |
| Other (expense) income | 309 | - |
| Loss before income tax expense | -95,426 | - |
| Income tax expense | 3,392 | - |
| Net loss | -98,818 | -60,096 |
| Depreciation and amortization | 615 | 252 |
| Stock-based compensation expense | 12,232 | 5,379 |
| Realized gain from sale of marketable securities | 1,165 | 587 |
| Non-cash operating lease expense (benefit) | - | 218 |
| Non cash operating lease expense | -33 | - |
| Amortization of premium on marketable securities | 29 | -7 |
| Foreign currency exchange loss (gain) | 7,364 | -485 |
| Non-cash interest expense and amortization of issuance costs | 7,116 | 3,453 |
| Fair value adjustment to derivative liability | -206 | -1,100 |
| Impairment of right of use assets | 1,190 | - |
| Research and development tax credit receivable | -9,790 | -826 |
| Accounts receivable, net | 3,853 | 1,926 |
| Inventory | 457 | - |
| Prepaid expenses and other assets | 4,760 | -1,597 |
| Accounts payable | 3,583 | 2,510 |
| Accrued expenses | - | -8,199 |
| Accrued expenses and other liabilities | -4,154 | - |
| Deferred revenue | 10,758 | 493 |
| Net cash used in operating activities | -72,483 | -54,502 |
| Purchases of marketable securities | 85,793 | 19,979 |
| Sales and maturities of marketable securities | 86,212 | 41,677 |
| Acquisition of property and equipment | 1,573 | 290 |
| Disposal of property and equipment | 12 | - |
| Capitalized website development costs | 247 | 147 |
| Net cash provided by (used in) investing activities | -1,389 | 21,261 |
| Proceeds from sale of convertible notes | 139,438 | - |
| Proceeds from the royalty agreement | -662 | 21,921 |
| Issuance of common stock from equity incentive plans | 2,539 | 595 |
| Issuance of common stock from employee stock purchase plan | 460 | 694 |
| Net cash provided by financing activities | 141,180 | 23,210 |
| Effect of exchange rate changes | 1,319 | 2,723 |
| Net increase in cash, cash equivalents and restricted cash | 68,627 | -7,308 |
| Cash and cash equivalents at beginning of period | 182,978 | - |
| Cash and cash equivalents at end of period | 244,297 | - |
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)